Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 8/2018

01-08-2018 | Review

Mucosal Ablation in Patients with Barrett’s Esophagus: Fry or Freeze?

Authors: Kavel Visrodia, Liam Zakko, Kenneth K. Wang

Published in: Digestive Diseases and Sciences | Issue 8/2018

Login to get access

Abstract

The management of Barrett’s esophagus and early esophageal adenocarcinoma has shifted away from esophagectomy and toward endoscopic techniques, including endoscopic resection and ablative therapies. The most commonly used ablative therapies are radiofrequency ablation and cryotherapy. Radiofrequency ablation has risen to the top of the management algorithm due to its favorable safety profile and established track record of efficacy in patients with dysplastic Barrett’s. Cryotherapy offers early promise as an alternatively safe and effective ablative modality. We review radiofrequency ablation and cryotherapy techniques, and updated data regarding their efficacy and safety as well as their roles in the management of Barrett’s esophagus.
Literature
1.
Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013;119:1149–1158.CrossRefPubMed
2.
Shaheen NJ, Falk GW, Iyer PG, et al. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111:30–50. (quiz 51).CrossRefPubMed
3.
Phoa KN, van Vilsteren FG, Weusten BL, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014;311:1209–1217.CrossRefPubMed
4.
5.
Kunzli HT, Scholvinck DW, Phoa KN, et al. Simplified protocol for focal radiofrequency ablation using the HALO90 device: short-term efficacy and safety in patients with dysplastic Barrett’s esophagus. Endoscopy. 2015;47:592–597.CrossRefPubMed
6.
Sharma VK, Wang KK, Overholt BF, et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett’s esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc. 2007;65:185–195.CrossRefPubMed
7.
Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360:2277–2288.CrossRefPubMed
8.
Duits LC, Phoa KN, Curvers WL, et al. Barrett’s oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel. Gut. 2015;64:700–706.CrossRefPubMed
9.
Curvers WL, ten Kate FJ, Krishnadath KK, et al. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105:1523–1530.CrossRefPubMed
10.
Shaheen NJ, Bulsiewicz WJ, Rothstein RI, et al. Eradication rates of Barrett’s esophagus using radiofrequency ablation (RFA): results from the U.S. RFA registry. Gastrointest Endosc. 2012;75:AB460.CrossRef
11.
Orman ES, Li N, Shaheen NJ. Efficacy and durability of radiofrequency ablation for Barrett’s Esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11:1245–1255.CrossRefPubMed
12.
Qumseya BJ, Wani S, Gendy S, et al. Disease progression in Barrett’s low-grade dysplasia with radiofrequency ablation compared with surveillance: systematic review and meta-analysis. Am J Gastroenterol. 2017;112:849–865.CrossRefPubMed
13.
van Vilsteren FG, Alvarez Herrero L, Pouw RE, et al. Predictive factors for initial treatment response after circumferential radiofrequency ablation for Barrett’s esophagus with early neoplasia: a prospective multicenter study. Endoscopy. 2013;45:516–525.CrossRefPubMed
14.
Gupta M, Iyer PG, Lutzke L, et al. Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett’s esophagus: results from a US Multicenter Consortium. Gastroenterology. 2013;145:79–86e1.CrossRefPubMedPubMedCentral
15.
Bulsiewicz WJ, Kim HP, Dellon ES, et al. Safety and efficacy of endoscopic mucosal therapy with radiofrequency ablation for patients with neoplastic Barrett’s esophagus. Clin Gastroenterol Hepatol. 2013;11:636–642.CrossRefPubMed
16.
Komanduri S, Kahrilas PJ, Krishnan K, et al. Recurrence of Barrett’s esophagus is rare following endoscopic eradication therapy coupled with effective reflux control. Am J Gastroenterol. 2017;112:556–566.CrossRefPubMed
17.
Fudman DI, Lightdale CJ, Poneros JM, et al. Positive correlation between endoscopist radiofrequency ablation volume and response rates in Barrett’s esophagus. Gastrointest Endosc. 2014;80:71–77.CrossRefPubMedPubMedCentral
18.
Pasricha S, Cotton C, Hathorn KE, et al. Effects of the learning curve on efficacy of radiofrequency ablation for Barrett’s esophagus. Gastroenterology. 2015;149:890–896e2.CrossRefPubMedPubMedCentral
19.
Qumseya BJ, Wani S, Desai M, et al. Adverse events after radiofrequency ablation in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14:1086–1095e6.CrossRefPubMed
20.
Shaheen NJ, Overholt BF, Sampliner RE, et al. Durability of radiofrequency ablation in Barrett’s esophagus with dysplasia. Gastroenterology. 2011;141:460–468.CrossRefPubMedPubMedCentral
21.
Desai M, Saligram S, Gupta N, et al. Efficacy and safety outcomes of multimodal endoscopic eradication therapy in Barrett’s esophagus-related neoplasia: a systematic review and pooled analysis. Gastrointest Endosc. 2017;85:482–495e4.CrossRefPubMed
22.
Hamade N, Sharma P. Ablation therapy for Barrett’s esophagus: new rules for changing times. Curr Gastroenterol Rep. 2017;19:48.CrossRefPubMed
23.
Das KK, Falk GW. Long-term outcomes for cryotherapy in Barrett’s esophagus with high-grade dysplasia: just cracking the ice. Gastrointest Endosc. 2017;86:633–635.CrossRefPubMed
24.
Ribeiro A, Bejarano P, Livingstone A, et al. Depth of injury caused by liquid nitrogen cryospray: study of human patients undergoing planned esophagectomy. Dig Dis Sci. 2014;59:1296–1301.CrossRefPubMed
25.
26.
Johnston MH, Eastone JA, Horwhat JD, et al. Cryoablation of Barrett’s esophagus: a pilot study. Gastrointest Endosc. 2005;62:842–848.CrossRefPubMed
27.
Dumot JA, Vargo JJ 2nd, Falk GW, et al. An open-label, prospective trial of cryospray ablation for Barrett’s esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. Gastrointest Endosc. 2009;70:635–644.CrossRefPubMed
28.
Ghorbani S, Tsai FC, Greenwald BD, et al. Safety and efficacy of endoscopic spray cryotherapy for Barrett’s dysplasia: results of the National Cryospray Registry. Dis Esophagus. 2016;29:241–247.CrossRefPubMed
29.
Shaheen NJ, Greenwald BD, Peery AF, et al. Safety and efficacy of endoscopic spray cryotherapy for Barrett’s esophagus with high-grade dysplasia. Gastrointest Endosc. 2010;71:680–685.CrossRefPubMedPubMedCentral
30.
Sengupta N, Ketwaroo GA, Bak DM, et al. Salvage cryotherapy after failed radiofrequency ablation for Barrett’s esophagus-related dysplasia is safe and effective. Gastrointest Endosc. 2015;82:443–448.CrossRefPubMed
31.
Scholvinck DW, Kunzli HT, Kestens C, et al. Treatment of Barrett’s esophagus with a novel focal cryoablation device: a safety and feasibility study. Endoscopy. 2015;47:1106–1112.CrossRefPubMed
32.
Kunzli HT, Scholvinck DW, Meijer SL, et al. Efficacy of the CryoBalloon Focal Ablation System for the eradication of dysplastic Barrett’s esophagus islands. Endoscopy. 2017;49:169–175.PubMed
33.
34.
Metadata
Title
Mucosal Ablation in Patients with Barrett’s Esophagus: Fry or Freeze?
Authors
Kavel Visrodia
Liam Zakko
Kenneth K. Wang
Publication date
01-08-2018
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 8/2018
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-018-5064-x

Other articles of this Issue 8/2018

Digestive Diseases and Sciences 8/2018 Go to the issue

Review

Point–Counterpoint: Screening and Surveillance for Barrett’s Esophagus, Is It Worthwhile?

Review

Screening for Barrett’s Esophagus: Are New High-Volume Methods Feasible?

Review

Are Gastric and Esophageal Metaplasia Relatives? The Case for Barrett’s Stemming from SPEM

Review

Management of Early-Stage Adenocarcinoma of the Esophagus: Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection

Review

Natural History of the Post-ablation Esophagus

Review

Molecular Evolution of Metaplasia to Adenocarcinoma in the Esophagus

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits